Do analysts rate OBSV or MIRA?

MIRA Pharmaceuticals has a consensus target price of $3.50, suggesting a potential upside of 425.21%. Given MIRA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe MIRA Pharmaceuticals is more favorable than ObsEva. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has preferable valuation & earnings, OBSV or MIRA?

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ObsEva N/A N/A -$58.38M -$0.92 N/A MIRA Pharmaceuticals N/A N/A -$10.44M -$1.24 N/A

Is OBSV or MIRA more profitable?

MIRA Pharmaceuticals' return on equity of -106.95% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets ObsEva N/A -416.36% -92.01% MIRA Pharmaceuticals N/A -106.95% -104.18%

Do analysts rate TAOX or OBSV?

Given ObsEva's higher possible upside, analysts clearly believe ObsEva is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is TAOX or OBSV more profitable?

ObsEva has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Synaptogenix's return on equity of -128.51% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets Synaptogenix -2,153.97% -128.51% -97.54% ObsEva N/A -416.36% -92.01%

Which has higher earnings and valuation, OBSV or VIRI?

Virios Therapeutics is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ObsEva N/A N/A -$58.38M -$0.92 N/A Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A

Is OBSV or VIRI more profitable?

Virios Therapeutics' return on equity of -130.33% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets ObsEva N/A -416.36% -92.01% Virios Therapeutics N/A -130.33% -115.00%

Do analysts recommend OBSV or ABVC?

Given ObsEva's higher possible upside, equities research analysts plainly believe ObsEva is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is OBSV or ABVC more profitable?

ABVC BioPharma's return on equity of -47.68% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets ObsEva N/A -416.36% -92.01% ABVC BioPharma N/A -47.68% -30.97%

Do analysts rate OBSV or QNTM?

Quantum Biopharma has a consensus target price of $8.00, suggesting a potential upside of 176.82%. Given Quantum Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Quantum Biopharma is more favorable than ObsEva. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, OBSV or QNTM?

Quantum Biopharma is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ObsEva N/A N/A -$58.38M -$0.92 N/A Quantum Biopharma N/A N/A -$26.17M -$5.49 N/A

Is OBSV or QNTM more profitable?

ObsEva's return on equity of -416.36% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets ObsEva N/A -416.36% -92.01% Quantum Biopharma N/A -582.23% -184.20%

ObsEva (OBSV) Competitors

Compare

OBSV vs. MIRA, TAOX, VIRI, ABVC, and QNTM

Should you buy ObsEva stock or one of its competitors? ObsEva's main competitors and comparable companies include MIRA Pharmaceuticals (MIRA), Synaptogenix (TAOX), Virios Therapeutics (VIRI), ABVC BioPharma (ABVC), and Quantum Biopharma (QNTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ObsEva compare to MIRA Pharmaceuticals?

ObsEva (NASDAQ:OBSV) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.24	N/A

MIRA Pharmaceuticals has a consensus target price of $3.50, suggesting a potential upside of 425.21%. Given MIRA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe MIRA Pharmaceuticals is more favorable than ObsEva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

MIRA Pharmaceuticals' return on equity of -106.95% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
MIRA Pharmaceuticals	N/A	-106.95%	-104.18%

In the previous week, MIRA Pharmaceuticals had 1 more articles in the media than ObsEva. MarketBeat recorded 1 mentions for MIRA Pharmaceuticals and 0 mentions for ObsEva. MIRA Pharmaceuticals' average media sentiment score of 1.82 beat ObsEva's score of 0.00 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
ObsEva	Neutral
MIRA Pharmaceuticals	Very Positive

17.5% of ObsEva shares are owned by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. 14.4% of ObsEva shares are owned by company insiders. Comparatively, 19.9% of MIRA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

ObsEva has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market.

Summary

MIRA Pharmaceuticals beats ObsEva on 10 of the 12 factors compared between the two stocks.

How does ObsEva compare to Synaptogenix?

Synaptogenix (NASDAQ:TAOX) and ObsEva (NASDAQ:OBSV) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 2.7% of Synaptogenix shares are held by company insiders. Comparatively, 14.4% of ObsEva shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Synaptogenix has a beta of 1.73, meaning that its stock price is 73% more volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

In the previous week, Synaptogenix had 3 more articles in the media than ObsEva. MarketBeat recorded 3 mentions for Synaptogenix and 0 mentions for ObsEva. Synaptogenix's average media sentiment score of 0.37 beat ObsEva's score of 0.00 indicating that Synaptogenix is being referred to more favorably in the media.

Company	Overall Sentiment
Synaptogenix	Neutral
ObsEva	Neutral

ObsEva has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Synaptogenix's return on equity of -128.51% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	-2,153.97%	-128.51%	-97.54%
ObsEva	N/A	-416.36%	-92.01%

Synaptogenix has higher revenue and earnings than ObsEva. Synaptogenix is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	96.29	-$28.74M	-$3.85	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

Given ObsEva's higher possible upside, analysts clearly believe ObsEva is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Synaptogenix and ObsEva tied by winning 7 of the 14 factors compared between the two stocks.

How does ObsEva compare to Virios Therapeutics?

ObsEva (NASDAQ:OBSV) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

17.5% of ObsEva shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 14.4% of ObsEva shares are held by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Virios Therapeutics is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

ObsEva has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market.

In the previous week, ObsEva's average media sentiment score of 0.00 equaled Virios Therapeutics'average media sentiment score.

Company	Overall Sentiment
ObsEva	Neutral
Virios Therapeutics	Neutral

Virios Therapeutics' return on equity of -130.33% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
Virios Therapeutics	N/A	-130.33%	-115.00%

Summary

ObsEva and Virios Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does ObsEva compare to ABVC BioPharma?

ObsEva (NASDAQ:OBSV) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

In the previous week, ABVC BioPharma had 1 more articles in the media than ObsEva. MarketBeat recorded 1 mentions for ABVC BioPharma and 0 mentions for ObsEva. ABVC BioPharma's average media sentiment score of 1.79 beat ObsEva's score of 0.00 indicating that ABVC BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
ObsEva	Neutral
ABVC BioPharma	Very Positive

ABVC BioPharma's return on equity of -47.68% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
ABVC BioPharma	N/A	-47.68%	-30.97%

Given ObsEva's higher possible upside, equities research analysts plainly believe ObsEva is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

17.5% of ObsEva shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 14.4% of ObsEva shares are held by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ABVC BioPharma has higher revenue and earnings than ObsEva. ABVC BioPharma is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
ABVC BioPharma	$510K	51.23	-$7.91M	-$0.30	N/A

ObsEva has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

Summary

ABVC BioPharma beats ObsEva on 9 of the 12 factors compared between the two stocks.

How does ObsEva compare to Quantum Biopharma?

ObsEva (NASDAQ:OBSV) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

Quantum Biopharma is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A

ObsEva has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

Quantum Biopharma has a consensus target price of $8.00, suggesting a potential upside of 176.82%. Given Quantum Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Quantum Biopharma is more favorable than ObsEva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

17.5% of ObsEva shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 14.4% of ObsEva shares are held by insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Quantum Biopharma had 8 more articles in the media than ObsEva. MarketBeat recorded 8 mentions for Quantum Biopharma and 0 mentions for ObsEva. Quantum Biopharma's average media sentiment score of 0.43 beat ObsEva's score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
ObsEva	Neutral
Quantum Biopharma	Neutral

ObsEva's return on equity of -416.36% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
Quantum Biopharma	N/A	-582.23%	-184.20%

Summary

ObsEva and Quantum Biopharma tied by winning 6 of the 12 factors compared between the two stocks.

Get ObsEva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBSV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OBSV vs. The Competition

Export

Metric	ObsEva	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.94M	$12.40B	$7.29B	$12.91B
Dividend Yield	N/A	2.63%	2.51%	22.89%
P/E Ratio	0.00	807.80	275.68	25.25
Price / Sales	N/A	748.52	562.78	78.51
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	N/A	9.19	10.54	5.92
Net Income	-$58.38M	$2.84B	$3.50B	$381.16M

ObsEva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50
MIRA MIRA Pharmaceuticals	3.0123 of 5 stars	$0.70 -1.1%	$3.50 +398.6%	-48.1%	$29.20M	N/A	N/A	2	Positive News
TAOX Synaptogenix	0.1522 of 5 stars	$3.81 -3.9%	N/A	-61.4%	$28.46M	$300K	N/A	4	High Trading Volume
VIRI Virios Therapeutics	N/A	$1.43 -5.9%	N/A	-74.5%	$27.54M	N/A	N/A	5	News Coverage
ABVC ABVC BioPharma	0.7496 of 5 stars	$0.98 -2.1%	N/A	-66.9%	$26.13M	$510K	N/A	19	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OBSV) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ObsEva (OBSV) Competitors

OBSV vs. MIRA, TAOX, VIRI, ABVC, and QNTM

How does ObsEva compare to MIRA Pharmaceuticals?

Summary

How does ObsEva compare to Synaptogenix?

Summary

How does ObsEva compare to Virios Therapeutics?

Summary

How does ObsEva compare to ABVC BioPharma?

Summary

How does ObsEva compare to Quantum Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBSV vs. The Competition

ObsEva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ObsEva (OBSV) Competitors

OBSV vs. MIRA, TAOX, VIRI, ABVC, and QNTM

How does ObsEva compare to MIRA Pharmaceuticals?

Which has preferable valuation & earnings, OBSV or MIRA?

Do analysts rate OBSV or MIRA?

Is OBSV or MIRA more profitable?

Does the media refer more to OBSV or MIRA?

Do insiders & institutionals hold more shares of OBSV or MIRA?

Which has more risk and volatility, OBSV or MIRA?

Summary

How does ObsEva compare to Synaptogenix?

Do institutionals & insiders believe in TAOX or OBSV?

Which has more volatility and risk, TAOX or OBSV?

Does the media favor TAOX or OBSV?

Is TAOX or OBSV more profitable?

Which has better valuation & earnings, TAOX or OBSV?

Do analysts rate TAOX or OBSV?

Summary

How does ObsEva compare to Virios Therapeutics?

Do institutionals & insiders hold more shares of OBSV or VIRI?

Which has higher earnings and valuation, OBSV or VIRI?

Which has more risk & volatility, OBSV or VIRI?

Does the media refer more to OBSV or VIRI?

Is OBSV or VIRI more profitable?

Summary

How does ObsEva compare to ABVC BioPharma?

Does the media refer more to OBSV or ABVC?

Is OBSV or ABVC more profitable?

Do analysts recommend OBSV or ABVC?

Do institutionals and insiders hold more shares of OBSV or ABVC?

Which has stronger valuation and earnings, OBSV or ABVC?

Which has more volatility and risk, OBSV or ABVC?

Summary

How does ObsEva compare to Quantum Biopharma?

Which has stronger valuation and earnings, OBSV or QNTM?

Which has more risk and volatility, OBSV or QNTM?

Do analysts rate OBSV or QNTM?

Do insiders and institutionals believe in OBSV or QNTM?

Does the media refer more to OBSV or QNTM?

Is OBSV or QNTM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBSV vs. The Competition

ObsEva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools